Phase II evaluation of desipramine for the treatment of hot flashes

Supportive Cancer Therapy

Volumn 4, Issue 4, 2007, Pages 219-224

  Barton, Debra L ^a,e   Loprinzi, Charles L ^a   Atherton, Pamela ^a   Raymond, Jane ^b   Shanafelt, Tait ^a   Hines, Stephanie ^c   Palmieri, Fran ^c   Rummans, Teresa ^a   Adjei, Alex A ^d   Sloan, Jeff ^a  

^a Mayo Clinic College of Medicine   (United States)

^b ALLEGHENY GENERAL HOSPITAL   (United States)

^c MAYO CLINIC   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e MAYO CLINIC   (United States)

Author keywords

Antidepressants; Menopause; Survivors; Symptom management

Indexed keywords

DESIPRAMINE; PLACEBO;

ADULT; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; FISHER EXACT TEST; HEADACHE; HOT FLUSH; HUMAN; INSOMNIA; MOOD CHANGE; MYALGIA; NAUSEA; NERVOUSNESS; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; SWEATING; TREATMENT DURATION;

EID: 35348962753     PISSN: 15432912     EISSN: None     Source Type: Journal    
DOI: 10.3816/SCT.2007.n.018     Document Type: Article

References (24)

1. Finck G, Barton DL, Loprinzi CL, et al. Definitions of hot flashes in breast cancer survivors. J Pain Symptom Manage 1998; 16:327-333.
2. Gracia CR, Freeman EW. Acute consequences of the menopausal transition: the rise of common menopausal symptoms. Endocrinol Metab Clin North Am 2004; 33:675-689.
3. Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the postmenopausal estrogen/progestin interventions trial. Obstet Gynecol 1998; 92:982-988.
4. Rossouw JE. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Women's Health Initiative Investigators. JAMA 2002; 288:321-333.
5. Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women. Women's Health Initiative Memory Study. JAMA 2004; 291:2959-2968.
6. Shanafelt TD, Barton DL, Adjei AA, et al. Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002; 77:1207-1218.
7. Carpenter JS, Gilchrist JM, Chen K, et al. Hot flashes, core body temperature, and metabolic parameters in breast cancer survivors. Menopause 2004; 11:375-381.
8. Berendsen HG. Hot flushes and serotonin. Menopause 2002; 8:30-34.
9. Sloan JA, Loprinzi CL, Novotny PJ, et al. Methodologic lessons learned from hot flash studies. J Clin Oncol 2001; 9:4280-4290.
10. Stearns V, Beebe K, Malini I, et al. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003; 289:2827-2834.
11. Stearns V, Slack R, Greep N, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized trial. J Clin Oncol 2005; 23:6919-6930.
12. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet 2000; 356:2059-2063.
13. Barton D, Loprinzi CL. Making sense of the evidence regarding non-hormonal treatments for hot flashes. Clin J Oncol Nurs 2004; 8:39-42.
14. Loprinzi CL, Barton DL, Carpenter LA, et al. Pilot evaluation of paroxetine for treating hot flashes in men. Mayo Clin Proc 2004; 79:1247-1251.
15. Barton DL, Loprinzi C, Novotny P, et al. Pilot evaluation of citalopram for the relief of hot flashes. J Support Oncol 2003; 1:47-52.
16. Perez D, Loprinzi C, Barton D, et al. Pilot evaluation of mirtazapine for the treatment of hot flashes. J Support Oncol 2004; 2:50-56.
17. Sloan JA, Frost MH, Berzon R, et al. The clinical significance of quality of life assessments in oncology: a summary for clinicians. Support Care Cancer 2006; 14:988-998.
18. Perez DF, Loprinzi CL, Sloan J, et al. Pilot evaluation of bupropion for the treatment of hot flashes. J Palliat Med 2006; 9:631-637.
19. Loprinzi CL, Pisansky TM, Fonseca R, et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998; 16:2377-2381.
20. Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center CCOP study. Ann Intern Med 2000; 132:788-793.
21. Freedman R. Biochemical, metabolic and vascular mechanisms in menopausal hot flashes. Fertil Steril 1998; 70:332-337.
22. Cone RD, Low MJ, Elmquist JK, et al. Neuroendocrinology. In: Larsen PR, Kronenberg HM, Melmed S, et al, eds. Williams Testbook of Endocrinology. 10th ed. Philadelphia, PA: Saunders; 2003.
23. Mizobe T, Nakajima Y, Sunaguchi M, et al. Clonidine produces a dose-dependent impairment of baroreflex-mediated thermoregulatory responses to positive end-expiratory pressure in anaesthetized humans. Br J Anaesth 2005; 94:536-541.
24. Loprinzi CL, Sloan JA, Perez EA. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002; 20:1578-1583.